As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

--INmune Bio Inc. announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at ...

INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be ...